Side Effects Sample Clauses

Side Effects. Each party shall advise the other as promptly as reasonably practical by telefax or overnight delivery service addressed to the attention of its Vice President, International Regulatory Affairs and Drug Safety and Surveillance (or, in LeukoSite's case, the party with similar responsibilities), of any unexpected side effect, adverse reaction or injury which has been brought to that party's attention at any place and which is alleged to have been caused by a Warner-LeukoSite Product. Warner shall have all rights and responsibility timely to report such side effects, adverse reaction or injury to regulatory authorities and others as appropriate.
Sample 1Sample 2Sample 3See All (15)
Side Effects. I understand that the common side effects of opioid medication include feeling sick (nausea), vomiting, constipation, drowsiness, dry mouth, and itchiness of the skin. With extended use I am likely to become tolerant to these side effects, except for constipation. Constipation is a very common side effect and I may be ordered medication to help with this problem. Other side effects which are rare include muscle jerks or shaking, muscle spasm, feeling weak, confusion, hallucinations, feeling disoriented, chills, changes in vision, difficulty passing urine, headaches, skin rashes, difficulty in thinking clearly, decreased sexual function, swelling of hands or feet, sweating, and decreased immune function.
Sample 1Sample 2Sample 3
Side Effects. Side effects are normal physical reactions to medications. Common side effects of opioids/narcotics include mood changes, drowsiness, dizziness, constipation, nausea, and confusion. Many of these side effects will resolve over days or weeks. Constipation often persists and may require additional medication. If other side effects persist, different opioids may be tried or they may be discontinued. You should NOT:
Sample 1Sample 2
Side Effects. I am to notify my provider of any adverse effects that I might experience while taking narcotic medications. Adverse effects include but are not limited to: over-­‐sedation, nausea, vomiting, constipation, euphoria, dysphoria, dizziness, sweating, itching, rashes, swelling, difficulty breathing, dysuria, dry mouth, insomnia, disorientation, decreased sex drive, and potency and abnormal jerking motions in the arms and legs. While on Narcotic medications, I will not operate a motor vehicle of any type or any other form of machinery that could cause injury to others or myself.
Sample 1
Side Effects. Ascent shall notify Unicycive immediately in writing upon becoming aware of any side effects arising from the use of the Compound in relation to the Project. Unicycive shall provide Ascent with information on side effects with respect to the Compound within a reasonable period of time after Unicycive becomes aware of any such side effects.
Sample 1
Side Effects. The most frequently reported side effects with sevelamer are all in the gastrointestinal category Common ( ≥1?100 <1/10) : Diarrhoea, dyspepsia, flatulence, abdominal pain Very common ( ≥1/10) : Nausea, vomiting, upper abdominal pain, constipation Full information on side effects is available in the Summary of Product Characteristic for Renagel® or Renvela® at the links below. Drug Interactions Interaction studies have not been conducted in patients on dialysis. In interaction studies in healthy volunteers, sevelamer hydrochloride, which contains the same active moiety as Renvela, decreased the bioavailability of ciprofloxacin by approximately 50% when co-administered with sevelamer hydrochloride in a single dose study. Consequently, Renvela should not be taken simultaneously with ciprofloxacin. Reduced levels of ciclosporin, mycophenolate mofetil and tacrolimus have been reported in transplant patients when co-administered with sevelamer hydrochloride without any clinical consequences (i.e graft rejection). The possibility of an interaction cannot be excluded and a close monitoring of blood concentrations of ciclosporin, mycophenolate mofetil and tacrolimus should be considered during the use of combination and after its withdrawal. Very rare cases of hypothyroidism have been reported in patients co-administered sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, and levothyroxine. Closer monitoring of thyroid stimulating hormone (TSH) levels is therefore recommended in patients receiving sevelamer carbonate and levothyroxine. Patients taking anti-arrhythmic medicinal products for the control of arrhythmias and anti-seizure medicinal products for the control of seizure disorders were excluded from clinical trials. Caution should be exercised when prescribing Renvela to patients also taking these medicinal products. In interaction studies in healthy volunteers, sevelamer hydrochloride, which contains the same active moiety as Renvela, had no effect on the bioavailability of digoxin, warfarin, enalapril or metoprolol. Renvela is not absorbed compound and may affect the bioavailability of other medicinal products. When administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after Renvela, or the physician should consider monitoring blood levels. Cost (Exc...
Sample 1
Side Effects. All medicines have side effects. The most common side effects of sleep medicines are: · Drowsiness · Dizziness · Lightheadedness · Difficulty with coordination Sleep medicines can make you sleepy during the day. How drowsy you feel depends upon how your body reacts to the medicine, which sleep medicine you are taking, and how large a dose your doctor has prescribed. Daytime drowsiness is best avoided by taking the lowest dose possible that will still help you sleep at night. Your doctor will work with you to find the dose of LUNESTA that is best for you. Some patients taking LUNESTA have reported next-day sleepiness. To manage these side effects while you are taking this medicine: · When you first start taking LUNESTA or any other sleep medicine, until you know whether the medicine will still have some effect on you the next day, use extreme care while doing anything that requires complete alertness, such as driving a car, operating machinery, or piloting an aircraft. · Do not drink alcohol when you are taking LUNESTA or any sleep medicine. Alcohol can increase the side effects of LUNESTA or any other sleep medicine. · Do not take any other medicines without asking your doctor first. This includes medicines you can buy without a prescription. Some medicines can cause drowsiness and are best avoided while taking LUNESTA. · Always take the exact dose of LUNESTA prescribed by your doctor. Never change your dose without talking to your doctor first.
Sample 1
Side Effects. See SPC or BNF for complete list of adverse effects Side effects may be short term and are usually dose dependent. They can often be prevented or relieved by a moderate reduction in dose. Type of adverse effect Action to be taken GI disturbances e.g. nausea, diarrhoea, dry mouth Ensure patient aware of need for fluid replacement Weight gain Monitor – Advise to avoid crash diets & sugary drinks. Oedema Monitor – may respond to dose reduction. Fine tremor Consider slight reduction in dose Polyuria (frequent urination) Polydipsia (frequent thirst) Advise re: fluid intake. May require investigation for diabetes insipidus if persistent Hypothyroidism Consider thyroid replacement if clinically indicated Signs of toxicity: Blurred vision, muscle weakness, drowsiness, coarse tremor, dysarthria, ataxia, confusion, convulsions, nausea & vomiting, ECG changes. Stop lithium immediately, measure lithium, creatinine, urea and electrolytes. Refer to hospital if clinical condition warrants MONITORING Serum Lithium monitoring Serum lithium must be monitored 5-7 days after initiation, then weekly until steady state is reached, then 3 monthly when stable (more frequently, typically 2 monthly in the elderly). More frequent monitoring is required following alteration of dosage; on development of intercurrent disease; in those with or at risk of cardiac, renal or thyroid disease; signs of manic or depressive relapse; following significant change in sodium or fluid intake; if an interacting drug is being taken or if signs of lithium toxicity occur. Lithium serum levels should be measured 12 hours after the previous dose. Patients taking lithium once daily at night should have the level measured in the morning 12 hours after the previous night time dose. Patients taking lithium twice daily should have the level measured in the morning 12 hours after the previous night time dose. The morning dose must be postponed until after the sample has been taken. Cardiac, renal, thyroid and calcium monitoring- minimum requirements Baseline ECG for those with existing cardiac disease or risk factors. Renal function- baseline and then every 6 months. Calcium- baseline and then every 6 months Thyroid function -TSH and T4 baseline and then every 6 months More frequent monitoring may be indicated in those with or at risk of cardiac, renal or thyroid disease. Weight should also be monitored Drug Interactions Refer to SPC or BNF appendix 1 for complete list Some medicines may result in increased li...
Sample 1

Related to Side Effects

  • Certain Corporate Events If a Fundamental Change, Make-Whole Fundamental Change (other than a Make-Whole Fundamental Change pursuant to clause (B) of the definition thereof) or Common Stock Change Event occurs (other than a merger or other business combination transaction that is effected solely to change the Company’s jurisdiction of incorporation and that does not constitute a Fundamental Change or a Make-Whole Fundamental Change), then, in each case, Holders may convert their Notes at any time from, and including, the effective date of such transaction or event to, and including, the thirty fifth (35th) Trading Day after such effective date (or, if such transaction or event also constitutes a Fundamental Change (other than an Exempted Fundamental Change), to, but excluding, the related Fundamental Change Repurchase Date); provided, however, that if the Company does not provide the notice referred to in the immediately following sentence by such effective date, then the last day on which the Notes are convertible pursuant to this sentence will be extended by the number of Business Days from, and including, such effective date to, but excluding, the date the Company provides such notice. No later than the Business Day after such effective date, the Company will send notice to the Holders, the Trustee and the Conversion Agent of such transaction or event, such effective date and the related right to convert Notes.

  • Termination Apart from a Change of Control If the Employee's employment with the Company terminates other than as a result of an Involuntary Termination within the twelve (12) months following a Change of Control, then the Employee shall not be entitled to receive severance or other benefits hereunder, but may be eligible for those benefits (if any) as may then be established under the Company's then existing severance and benefits plans and policies at the time of such termination.

  • Date on Which Exercise is Effective Each person in whose name any certificate for shares is issued upon the exercise of Rights shall for all purposes be deemed to have become the holder of record of the shares represented thereby on the date upon which the Rights Certificate evidencing such Rights was duly surrendered and payment of the Exercise Price for such Rights (and any applicable taxes and other governmental charges payable by the exercising holder hereunder) was made; provided, however, that if the date of such surrender and payment is a date upon which the stock transfer books of the Company are closed, such person shall be deemed to have become the record holder of such shares on, and such certificate shall be dated, the next succeeding Business Day on which the stock transfer books of the Company are open.

  • Termination Apart from Change of Control In the event the Employee’s employment is terminated for any reason, either prior to the occurrence of a Change of Control or after the twelve (12) month period following a Change of Control, then the Employee shall be entitled to receive severance and any other benefits only as may then be established under the Company’s (or any subsidiary’s) then existing severance and benefits plans or pursuant to other written agreements with the Company.

  • Payment on Change of Control In the event that a Change of Control of the Company occurs while this Note remains outstanding, upon the written consent of the Majority Holders, the Company shall pay to the Holder at the closing of such Change of Control a cash amount equal to three (3) times the outstanding principal amount of such Note, together with all interest accrued thereon. A “Change of Control” means: (i) a merger or consolidation of the Company (or of a subsidiary of the Company) in which outstanding shares of the Company (or of a subsidiary of the Company) are exchanged for securities or other consideration issued, or caused to be issued, by the acquiring corporation or its subsidiary and after which the Company’s stockholders own less than 50% of the voting stock of the surviving company (other than a bona fide equity financing or a mere reincorporation transaction), (ii) a sale or other disposition of all or substantially all of the assets of the Company and its subsidiaries, taken as a whole, (iii) a transfer of more than 50% of the Company’s voting securities to any person or group of persons or (iv) any Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, as amended from time to time. For the avoidance of doubt, if this Note is converted pursuant to Section 2(b), Holder shall not be entitled to any payment pursuant to this Section 3.

  • Certain Effects of the Merger At and as of the Effective Time, (a) the Company will be merged with and into Apple in accordance with the provisions of the BCA, (b) the Company will cease to exist as a separate legal entity, (c) Apple will be the Surviving Corporation and, as such, will, all with the effect provided by the BCA, (i) possess all the properties and rights, and be subject to all the restrictions and duties, of the Company and Apple and (ii) be governed by the laws of the State of Delaware, (d) the Charter Documents of Apple then in effect will become and thereafter remain (until changed in accordance with (i) the applicable law (in the case of the articles of incorporation) or (ii) its terms (in the case of the bylaws)) the Charter Documents of the Surviving Corporation, (e) the board of directors of Apple immediately prior to the Effective Time will be the board of directors of the Surviving Corporation, and those persons will hold the office of director of the Surviving Corporation subject to the provisions of the applicable laws of the State of Delaware and the Charter Documents of the Surviving Corporation, and (f) the officers of Apple immediately prior to the Effective Time will be the respective officers of the Surviving Corporation, subject to the provisions of the Charter Documents of the Surviving Corporation, until that person's successor is duly elected to, and, if necessary, qualified for, that office.

  • Termination on Change of Control 26.12.1 The Supplier shall notify the Authority immediately in writing if the Supplier undergoes a change of control within the meaning of Section 450 of the Corporation Tax Act 2010 ("Change of Control") and provided this does not contravene any Law shall notify the Authority immediately in writing of any circumstances suggesting that a Change of Control is planned or in contemplation. The Authority may terminate this Framework Agreement by giving notice in writing to the Supplier with immediate effect within six (6) Months of:

  • Effect of Recapitalizations, Reclassifications and Changes of the Common Stock (a) In the case of:

  • Repurchase Events By its execution of the Further Transfer Agreements to which it is a party, the Seller shall acknowledge the assignment by Ally Auto of such of its right, title and interest in, to and under this Agreement and the First Step Receivables Assignment to the Issuing Entity as shall be provided in the Further Transfer Agreements. The Seller hereby covenants and agrees with Ally Auto for the benefit of Ally Auto and the Interested Parties that in the event of a breach of any of the Seller’s representations and warranties contained in Section 3.01 hereof with respect to any Receivable (a “Repurchase Event”), the Seller will repurchase such Receivable from the Issuing Entity (if the Issuing Entity is then the Owner of such Receivable) on the date and for the amount specified in the Further Transfer Agreements, without further notice from Ally Auto hereunder. Upon the occurrence of a Repurchase Event with respect to a Receivable for which Ally Auto is the Owner, the Seller agrees to repurchase such Receivable from Ally Auto for an amount and upon the same terms as the Seller would be obligated to repurchase such Receivable from the Issuing Entity if the Issuing Entity was then the Owner thereof, and upon payment of such amount, the Seller shall have such rights with respect to such Receivable as if the Seller had purchased such Receivable from the Issuing Entity as the Owner thereof. It is understood and agreed that the obligation of the Seller to repurchase any Receivable as to which a breach has occurred and is continuing shall, if such obligation is fulfilled, constitute the sole remedy against the Seller for such breach available to Ally Auto or any Interested Party.

  • Transfer to Avoid Termination Event If either an Illegality under Section 5(b)(i)(1) or a Tax Event occurs and there is only one Affected Party, or if a Tax Event Upon Merger occurs and the Burdened Party is the Affected Party, the Affected Party will, as a condition to its right to designate an Early Termination Date under Section 6(b)(iv), use all reasonable efforts (which will not require such party to incur a loss, excluding immaterial, incidental expenses) to transfer within 20 days after it gives notice under Section 6(b)(i) all its rights and obligations under this Agreement in respect of the Affected Transactions to another of its Offices or Affiliates so that such Termination Event ceases to exist. If the Affected Party is not able to make such a transfer it will give notice to the other party to that effect within such 20 day period, whereupon the other party may effect such a transfer within 30 days after the notice is given under Section 6(b)(i). Any such transfer by a party under this Section 6(b)(ii) will be subject to and conditional upon the prior written consent of the other party, which consent will not be withheld if such other party's policies in effect at such time would permit it to enter into transactions with the transferee on the terms proposed.